Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
3 Months : From Sep 2019 to Dec 2019
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Monday said it filed a supplemental biologics-license application with the U.S. Food and Drug Administration seeking first-in-class approval of Tremfya for adults with active psoriatic arthritis.
Janssen said it also expects to submit a marketing application to the European Medicines Agency for the same indication before the end of the year.
The company said it is estimated that at least one million Americans suffer from psoriatic arthritis, chronic disease characterized by joint inflammation, enthesitis, dactylitis and the skin manifestations of psoriasis.
The FDA approved Tremfya in July 2017 for adults with moderate to severe plaque psoriasis.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
September 16, 2019 08:01 ET (12:01 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.